Guangzhou Bio-gene Technology Co., Ltd

This early-stage study is testing a new type of CAR-T cell therapy that targets two proteins (BCMA and GPRC5D) on cancer cells in patients with multiple myeloma that has come back or stopped responding to other treatments. The main goals are to find a safe dose and see if the tre…

This early-stage study is testing the safety and initial effectiveness of a new type of CAR-T cell therapy for people with relapsed or refractory multiple myeloma who have already tried at least three other treatments. Doctors will collect a patient's own immune cells, modify the…

This early-stage study is testing the safety and initial effectiveness of a new type of CAR-T cell therapy called BAFFR CAR-T in adults with B-cell leukemia or lymphoma that has come back or not responded to standard treatments. Doctors will give the therapy to a small group of p…